Antibody-drug conjugate helps patients with metastatic non-small cell lung cancer live longer, delaying disease progression

BYLINE: Denise Heady Newswise — Treatment with datopotamab deruxtecan (Dato-DXd), a novel Trop-2 directed antibody-drug conjugate, was found to significantly improve progression-free survival in patients with metastatic non-small…

Read more Antibody-drug conjugate helps patients with metastatic non-small cell lung cancer live longer, delaying disease progression